GlassScriptPhysician profile
Jordan A Shavit
NPI 1518009729
$190,379.25
in general payments reported to CMS, 2019-2025
14 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $13K · 2021: $8,749 · 2022: $28K · 2023: $36K · 2024: $41K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $85K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $8,704 · Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,693.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,938.34 |
| Travel and Lodging | $8,704.36 |
| Food and Beverage | $1,759.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,884.34 | 2019-2025 | |
| Novo Nordisk INC | $29,048.97 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20,750.66 | 2020-2025 | Adynovate |
| Genentech USA, INC. | $13,610.57 | 2022-2025 | Hemlibra |
| Shire North American Group INC | $12,601.49 | 2019 | |
| Biomarin Pharmaceutical INC. | $12,280.17 | 2019-2024 | Roctavian |
| Pfizer INC. | $12,056.39 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $7,424.39 | 2019 | |
| Spark Therapeutics, INC. | $3,837.02 | 2019 | |
| Medexus Pharma, INC. | $2,600.00 | 2023 | Ixinity |
| Hema Biologics, LLC | $2,519.90 | 2021 | |
| Swedish Orphan Biovitrum Ab | $1,980.00 | 2021 | |
| Csl Behring | $1,749.04 | 2021 | |
| Agios Pharmaceuticals, INC. | $36.31 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Shavit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.